Combination treatments with CDK4/6 inhibitors and SYD985 have demonstrated superior anti-tumor effects in patient-derived xenografts, suggesting a viable strategy for tumors with heterogeneous HER2 expression [38]. This evidence concerns the gene ERBB2 and neoplasm.